Genelux (GNLX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.42, -2.42% vs the prior close of $2.48.
- Volume 277.87K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GNLX dips 2.4% to $2.42. Closed at $2.42, -2.42% vs the prior close of $2.48. Day range $2.36–$2.52, opened at $2.48.
GNLX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GNLX dips 2.4% to $2.42
- Closed at $2.42, -2.42% vs the prior close of $2.48. Day range $2.36–$2.52, opened at $2.48.
- Volume was 277.87K shares, 0.9x its 50-day average of 293.55K.
- Price is -5.9% vs its 50-day average ($2.57) and -12.0% vs its 200-day average ($2.75).
- 52-week range $2.29–$8.53; today's close sits at 2% of that range, 71.6% below the 52-week high.
Oct 15, 2026 — GNLX jumps 6.9% to $2.48 on 2.7x normal volume
- Closed at $2.48, +6.90% vs the prior close of $2.32. Day range $2.33–$2.51, opened at $2.40.
- Volume was 796.50K shares, 2.7x its 50-day average of 296.62K — unusually heavy trading.
- Price is -3.7% vs its 50-day average ($2.58) and -10.2% vs its 200-day average ($2.76).
- 52-week range $2.29–$8.53; today's close sits at 3% of that range, 70.9% below the 52-week high.
Oct 14, 2026 — GNLX slides 7.9% to $2.32, a 6-month low, 3 down days in a row
- Closed at $2.32, -7.94% vs the prior close of $2.52. Day range $2.32–$2.52, opened at $2.48.
- Volume was 410.40K shares, 1.3x its 50-day average of 304.16K.
- Price is -10.0% vs its 50-day average ($2.58) and -16.3% vs its 200-day average ($2.77).
- 52-week range $2.29–$8.53; today's close sits at 0% of that range, 72.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — GNLX dips 1.0% to $2.52
- Closed at $2.52, -0.98% vs the prior close of $2.55. Day range $2.48–$2.54, opened at $2.53.
- Volume was 151.80K shares, 0.5x its 50-day average of 305.52K — lighter than usual.
- Price is -2.6% vs its 50-day average ($2.59) and -9.4% vs its 200-day average ($2.78).
- 52-week range $2.29–$8.53; today's close sits at 4% of that range, 70.5% below the 52-week high.
Oct 12, 2026 — GNLX dips 0.6% to $2.55
- Closed at $2.55, -0.59% vs the prior close of $2.56. Day range $2.51–$2.59, opened at $2.59.
- Volume was 72.60K shares, 0.2x its 50-day average of 311.56K — lighter than usual.
- Price is -2.0% vs its 50-day average ($2.60) and -8.8% vs its 200-day average ($2.79).
- 52-week range $2.29–$8.53; today's close sits at 4% of that range, 70.2% below the 52-week high.
Oct 9, 2026 — GNLX rises 2.4% to $2.56
- Closed at $2.56, +2.40% vs the prior close of $2.50. Day range $2.47–$2.57, opened at $2.48.
- Volume was 154.60K shares, 0.5x its 50-day average of 313.20K — lighter than usual.
- Price is -1.7% vs its 50-day average ($2.60) and -8.5% vs its 200-day average ($2.80).
- 52-week range $2.29–$8.53; today's close sits at 4% of that range, 70.0% below the 52-week high.
Oct 8, 2026 — GNLX dips 0.8% to $2.50, 3 down days in a row
- Closed at $2.50, -0.79% vs the prior close of $2.52. Day range $2.42–$2.53, opened at $2.47.
- Volume was 259.10K shares, 0.8x its 50-day average of 310.53K.
- Price is -4.4% vs its 50-day average ($2.61) and -11.0% vs its 200-day average ($2.81).
- 52-week range $2.29–$8.53; today's close sits at 3% of that range, 70.7% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — GNLX dips 0.8% to $2.52 on 1.8x normal volume
- Closed at $2.52, -0.79% vs the prior close of $2.54. Day range $2.46–$2.59, opened at $2.52.
- Volume was 551.00K shares, 1.8x its 50-day average of 302.42K — unusually heavy trading.
- Price is -3.8% vs its 50-day average ($2.62) and -10.5% vs its 200-day average ($2.82).
- 52-week range $2.29–$8.53; today's close sits at 4% of that range, 70.5% below the 52-week high.
Oct 6, 2026 — GNLX dips 2.3% to $2.54
- Closed at $2.54, -2.31% vs the prior close of $2.60. Day range $2.52–$2.63, opened at $2.58.
- Volume was 77.60K shares, 0.3x its 50-day average of 302.20K — lighter than usual.
- Price is -3.4% vs its 50-day average ($2.63) and -10.1% vs its 200-day average ($2.82).
- 52-week range $2.29–$8.53; today's close sits at 4% of that range, 70.2% below the 52-week high.
Oct 5, 2026 — GNLX rises 1.6% to $2.60
- Closed at $2.60, +1.56% vs the prior close of $2.56. Day range $2.46–$2.66, opened at $2.55.
- Volume was 317.30K shares, 1.1x its 50-day average of 298.92K.
- Price is -1.4% vs its 50-day average ($2.64) and -8.2% vs its 200-day average ($2.83).
- 52-week range $2.29–$8.53; today's close sits at 5% of that range, 69.5% below the 52-week high.
Oct 2, 2026 — GNLX rises 1.6% to $2.56
- Closed at $2.56, +1.59% vs the prior close of $2.52. Day range $2.52–$2.59, opened at $2.55.
- Volume was 278.10K shares, 0.9x its 50-day average of 296.19K.
- Price is -3.1% vs its 50-day average ($2.64) and -9.9% vs its 200-day average ($2.84).
- 52-week range $2.29–$8.53; today's close sits at 4% of that range, 70.0% below the 52-week high.
GNLX latest news & SEC filings
Every SEC filing by or about GNLX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cappello Joseph sold 10,257 shares at $2.74 (≈$28.10K) on Aug 31, 2026
- Cappello Joseph sold 10,257 shares at $2.74 (≈$28.10K) on Aug 31, 2026
- Cappello Joseph sold 10,257 shares at $2.74 (≈$28.10K) on Aug 31, 2026
- Cappello Joseph sold 10,257 shares at $2.74 (≈$28.10K) on Aug 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Zindrick Thomas sold 34,463 shares at $2.67 (≈$92.02K) on Aug 31, 2026
- Zindrick Thomas sold 34,463 shares at $2.67 (≈$92.02K) on Aug 31, 2026
- Zindrick Thomas sold 34,463 shares at $2.67 (≈$92.02K) on Aug 31, 2026
- Zindrick Thomas sold 34,463 shares at $2.67 (≈$92.02K) on Aug 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Yu Yong sold 9,683 shares at $2.75 (≈$26.63K) on Aug 31, 2026
- Yu Yong sold 9,683 shares at $2.75 (≈$26.63K) on Aug 31, 2026
- Yu Yong sold 9,683 shares at $2.75 (≈$26.63K) on Aug 31, 2026
- Yu Yong sold 9,683 shares at $2.75 (≈$26.63K) on Aug 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$9.47M (prior year -$7.46M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.21 (prior year -$0.20) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Yu Yong sold 653 shares at $2.94 (≈$1.92K) on Aug 4, 2026
- Yu Yong sold 653 shares at $2.94 (≈$1.92K) on Aug 4, 2026
- Yu Yong sold 653 shares at $2.94 (≈$1.92K) on Aug 4, 2026
- Yu Yong sold 653 shares at $2.94 (≈$1.92K) on Aug 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cappello Joseph sold 653 shares at $2.95 (≈$1.93K) on Aug 4, 2026
- Cappello Joseph sold 653 shares at $2.95 (≈$1.93K) on Aug 4, 2026
- Cappello Joseph sold 653 shares at $2.95 (≈$1.93K) on Aug 4, 2026
- Cappello Joseph sold 653 shares at $2.95 (≈$1.93K) on Aug 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Zindrick Thomas sold 3,023 shares at $2.95 (≈$8.92K) on Aug 4, 2026
- Zindrick Thomas sold 3,023 shares at $2.95 (≈$8.92K) on Aug 4, 2026
- Zindrick Thomas sold 3,023 shares at $2.95 (≈$8.92K) on Aug 4, 2026
- Zindrick Thomas sold 3,023 shares at $2.95 (≈$8.92K) on Aug 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade GNLX
- Last results release: Mar 25, 2025 (8-K Item 2.02). Previous ones: Feb 2, 2024. Based on that rhythm, the next report is likely around Jun 24, 2025 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.27% (largest 7.9%).
- Liquidity: about 240.99K shares (≈$583.19K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.42 vs a range of $2.29–$8.53 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Thomas Zindrick sold 34,463 shares on Aug 31, 2026.
- Latest filings: 10-Q Aug 13, 2026; 8-K Jun 22, 2026; 10-Q May 7, 2026.
- Share count: 45.25M shares outstanding (Aug 11, 2026), +19.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GNLX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.48 | 2.52 | 2.36 | 2.42 | 277.87K |
| Oct 15, 2026 | 2.40 | 2.51 | 2.33 | 2.48 | 796.50K |
| Oct 14, 2026 | 2.48 | 2.52 | 2.32 | 2.32 | 410.40K |
| Oct 13, 2026 | 2.53 | 2.54 | 2.48 | 2.52 | 151.80K |
| Oct 12, 2026 | 2.59 | 2.59 | 2.51 | 2.55 | 72.60K |
| Oct 9, 2026 | 2.48 | 2.57 | 2.47 | 2.56 | 154.60K |
| Oct 8, 2026 | 2.47 | 2.53 | 2.42 | 2.50 | 259.10K |
| Oct 7, 2026 | 2.52 | 2.59 | 2.46 | 2.52 | 551.00K |
| Oct 6, 2026 | 2.58 | 2.63 | 2.52 | 2.54 | 77.60K |
| Oct 5, 2026 | 2.55 | 2.66 | 2.46 | 2.60 | 317.30K |
| Oct 2, 2026 | 2.55 | 2.59 | 2.52 | 2.56 | 278.10K |
| Oct 1, 2026 | 2.53 | 2.56 | 2.46 | 2.52 | 200.90K |
| Sep 30, 2026 | 2.47 | 2.55 | 2.47 | 2.53 | 236.90K |
| Sep 29, 2026 | 2.48 | 2.56 | 2.41 | 2.45 | 164.90K |
| Sep 28, 2026 | 2.46 | 2.50 | 2.41 | 2.47 | 103.70K |
| Sep 25, 2026 | 2.47 | 2.54 | 2.42 | 2.48 | 139.60K |
| Sep 24, 2026 | 2.51 | 2.52 | 2.41 | 2.43 | 152.00K |
| Sep 23, 2026 | 2.61 | 2.64 | 2.50 | 2.52 | 115.80K |
| Sep 22, 2026 | 2.55 | 2.63 | 2.52 | 2.61 | 161.80K |
| Sep 21, 2026 | 2.57 | 2.59 | 2.51 | 2.56 | 197.30K |
About Genelux
Genelux (GNLX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WESTLAKE VILLAGE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1231457.
GNLX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mary Mirabelli | Director | Jun 18, 2026 |
| John W Smither | Director | Jul 2, 2026 |
| John Thomas | Director | Jun 18, 2026 |
| James L Tyree | Director | Jun 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Joseph Cappello | Chief Technical Officer | Sep 2, 2026 |
| Eric Groen | General Counsel | Jun 18, 2026 |
| Jason Litten | Chief Medical Officer | Jan 7, 2026 |
| Matthew Pulisic | Chief Financial Officer | Jun 18, 2026 |
| Ralph Smalling | Head of Regulatory | Jun 4, 2026 |
| Yong Yu | Chief Scientific Officer | Sep 2, 2026 |
| Thomas Zindrick | President and CEO | Sep 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 31, 2026 | Thomas Zindrick | Sale | 34,463 | $2.67 |
| Aug 31, 2026 | Thomas Zindrick | Sale | 34,463 | $2.67 |
| Aug 31, 2026 | Thomas Zindrick | Sale | 34,463 | $2.67 |
| Aug 31, 2026 | Thomas Zindrick | Sale | 34,463 | $2.67 |
| Aug 31, 2026 | Joseph Cappello | Sale | 10,257 | $2.74 |
| Aug 31, 2026 | Joseph Cappello | Sale | 10,257 | $2.74 |
| Aug 31, 2026 | Joseph Cappello | Sale | 10,257 | $2.74 |
| Aug 31, 2026 | Joseph Cappello | Sale | 10,257 | $2.74 |
| Aug 31, 2026 | Yong Yu | Sale | 9,683 | $2.75 |
| Aug 31, 2026 | Yong Yu | Sale | 9,683 | $2.75 |
| Aug 31, 2026 | Yong Yu | Sale | 9,683 | $2.75 |
| Aug 31, 2026 | Yong Yu | Sale | 9,683 | $2.75 |
| Aug 4, 2026 | Thomas Zindrick | Sale | 3,023 | $2.95 |
| Aug 4, 2026 | Thomas Zindrick | Sale | 3,023 | $2.95 |
| Aug 4, 2026 | Thomas Zindrick | Sale | 3,023 | $2.95 |
GNLX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $8.00K | $-32.15M | -0.86 | $-25.27M |
| Dec 31, 2024 | $8.00K | $-29.87M | -0.95 | $-21.23M |
| Dec 31, 2023 | $170.00K | $-28.30M | -1.16 | $-20.27M |
| Dec 31, 2022 | $11.07M | $-5.21M | -0.57 | $-3.57M |
Latest balance sheet: total assets $26.20M, total liabilities $10.09M, cash $9.18M (as of Jun 30, 2026).
GNLX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Mar 25, 2025 | 8-K Item 2.02 (results) | $3.40 |
| Feb 2, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GNLX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.